Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity

Neuropsychopharmacology

Volumn 38, Issue 8, 2013, Pages 1585-1597

  Van'T Veer, Ashlee ^a   Bechtholt, Anita J ^a   Onvani, Sara ^a   Potter, David ^a   Wang, Yujun ^b   Liu Chen, Lee Yuan ^b   Schütz, Günther ^c   Chartoff, Elena H ^a   Rudolph, Uwe ^a   Cohen, Bruce M ^a   Carlezon Jr , William A ^a  

^a MCLEAN HOSPITAL   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

anxiety; cocaine.; dopamine; kappa opioid receptor; mutation

Indexed keywords

COCAINE; CRE RECOMBINASE; DOPAMINE TRANSPORTER; KAPPA OPIATE RECEPTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AUTORADIOGRAPHY; BODY WEIGHT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENE MUTATION; GENOTYPE; HEARING; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MAZE TEST; MESENCEPHALON; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SENSITIZATION; STARTLE REFLEX; TACTILE STIMULATION; TRANQUILIZING ACTIVITY; VISION;

ANIMALS; ANTI-ANXIETY AGENTS; BENZENEACETAMIDES; BRAIN; COCAINE; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEURONAL PLASTICITY; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA;

EID: 84879413396     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.58     Document Type: Article

References (62)

1. Beardsley PM, Howard JL, Shelton KL, Carroll FI (2005). Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 183: 118-126. (Pubitemid 41484188)
2. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ et al (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311: 864-868. (Pubitemid 43228853)
3. Bevins RA (2005). The reference-dose place conditioning procedure yields a graded dose-effect function. Int J Comp Psychol 18: 101-111. (Pubitemid 40911708)
4. Bruchas MR, Chavkin C (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharma-cology 210: 137-147.
5. Bruchas MR, Land BB, Chavkin C (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314: 44-55.
6. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB et al (2011). Selective p38alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 71: 498-511.
7. Carlezon WA Jr., Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS et al (2006). Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447. (Pubitemid 41832624)
8. Carlezon WA Jr., Beguin C, Knoll AT, Cohen BM (2009). Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther 123: 334-343.
9. Carlezon WA Jr., Carroll FI (2013). Development of kappa opioid receptor antagonists. J Med Chem; e-pub ahead of print 14 February 2013. doi:10.1021/jm301783x.
10. Carlezon WA Jr., Chartoff EH (2007). Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2: 2987-2995.
11. Carlezon WA Jr., Nestler EJ (2002). Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci 25: 610-615.
12. Carr GV, Lucki I (2010). Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between Wistar Kyoto and Sprague Dawley rats. Psychopharmacology 210: 295-302.
13. Chavkin C, James IF, Goldstein A (1982). Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215: 413-415. (Pubitemid 12132127)
14. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS (2005). Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25: 5029-5037. (Pubitemid 40712846)
15. Cohen BM, Murphy B (2008). The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol 11: 243-247. (Pubitemid 351231830)
16. Crawley JN (2007). What's Wrong with My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice. 2nd edn John Wiley: Hoboken.
17. Devine DP, Leone P, Pocock D, Wise RA (1993). Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J Pharmacol Exp Ther 266: 1236-1246. (Pubitemid 24175764)
18. Di Chiara G, Imperato A (1988). Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244: 1067-1080. (Pubitemid 18090131)
19. Dietis N, Rowbotham DJ, Lambert DG (2011). Opioid receptor subtypes: fact or artifact? Br J Anaesth 107: 8-18.
20. Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E et al (2009). Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci 29: 1855-1859.
21. Donzanti BA, Althaus JS, Payson MM, Von Voigtlander PF (1992). Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Res Commun Chem Pathol Pharmacol 78: 193-210.
22. Feil S, Valtcheva N, Feil R (2009). Inducible Cre mice. Methods Mol Biol 530: 343-363.
23. File SE (1990). New strategies in the search for anxiolytics. Drug Des Deliv 5: 195-201. (Pubitemid 20106971)
24. Ford CP, Beckstead MJ, Williams JT (2007). Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents. J Neurophysiol 97: 883-891. (Pubitemid 46143402)
25. Fox MW (1965). The visual cliff test for the study of visual depth perception in the mouse. Anim Behav 13: 232-233.
26. Graham DL, Krishnan V, Larson EB, Graham A, Edwards S, Bachtell RK et al (2009). Tropomyosin-related kinase B in the mesolimbic dopamine system: region-specific effects on cocaine reward. Biol Psychiatry 65: 696-701.
27. Haller J, Aliczki M, Gyimesine Pelczer K (2012). Classical and novel approaches to the preclinical testing of anxiolytics: A critical evaluation. Neurosci Biobehav Rev; epub ahead of print 12 September 2012. doi:10.1016/j.neubiorev.2012.09.001.
28. Inan S, Cowan A (2004). Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol 502: 233-237. (Pubitemid 39336489)
29. Jackson KJ, Carroll FI, Negus SS, Damaj MI (2010). Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. Psycho-pharmacology 210: 285-294.
30. Janssen PA, Niemegeers CJ, Dony JG (1963). The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawl reflex in rats. Arzneimittel-forschung 13: 502-507.
31. Knoll AT, Carlezon WA Jr. (2010). Dynorphin, stress, and depression. Brain Res 1314: 56-73.
32. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr. (2007). Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323: 838-845. (Pubitemid 350146065)
33. Koff JM, Shuster L, Miller LG (1994). Chronic cocaine administration is associated with behavioral sensitization and time-dependent changes in striatal dopamine transporter binding. J Pharmacol Exp Ther 268: 277-282. (Pubitemid 24039099)
34. La Regina A, Petrillo P, Sbacchi M, Tavani A (1988). Interaction of U-69, 593 with mu-, alpha- and kappa-opioid binding sites and its analgesic and intestinal effects in rats. Life Sci 42: 293-301. (Pubitemid 18038331)
35. Lett BT (1989). Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology 98: 357-362. (Pubitemid 19162424)
36. Maisonneuve IM, Archer S, Glick SD (1994). U50, 488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181: 57-60.
37. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988). Anatomy of CNS opioid receptors. Trends Neurosci 11: 308-314.
38. Margolis EB, Hjelmstad GO, Bonci A, Fields HL (2003). Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23: 9981-9986. (Pubitemid 37392543)
39. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL (2006). Kappa opioids selectively control dopaminer-gic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA 103: 2938-2942.
40. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674-5683. (Pubitemid 36807845)
41. Muschamp JW, Nemeth CL, Robison AJ, Nestler EJ, Carlezon WA Jr. (2012). DeltaFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488. Biol Psychiatry 71: 44-50.
42. Parlato R, Rieker C, Turiault M, Tronche F, Schutz G (2006). Survival of DA neurons is independent of CREM upregulation in absence of CREB. Genesis 44: 454-464. (Pubitemid 44684992)
43. Pasternak GW (1980). Multiple opiate receptors: [3H]ethylketocy-clazocine receptor binding and ketocyclazocine analgesia. Proc Natl Acad Sci USA 77: 3691-3694. (Pubitemid 10012924)
44. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986). Psychotomimesis mediated by kappa opiate receptors. Science 233: 774-776. (Pubitemid 16016229)
45. Piazza PV, Deminiere JM, Le Moal M, Simon H (1989). Factors that predict individual vulnerability to amphetamine self-administration. Science 245: 1511-1513. (Pubitemid 19243245)
46. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmaco-dyn Ther 229: 327-336. (Pubitemid 8225714)
47. Prut L, Belzung C (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3-33. (Pubitemid 36205070)
48. Robinson TE, Berridge KC (2000). The psychology and neurobiol-ogy of addiction: an incentive-sensitization view. Addiction 95(Suppl 2): S91-117.
49. Rogala B, Li Y, Li S, Chen X, Kirouac GJ (2012). Effects of a Post-shock injection of the kappa opioid receptor antagonist norbinaltorphimine (norBNI) on fear and anxiety in rats. PloS one 7: e49669.
50. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V et al (2007). Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA 104: 6406-6411. (Pubitemid 47186107)
51. Shippenberg TS, Heidbreder C (1995). Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. J Pharmacol Exp Ther 273: 808-815.
52. Svingos AL, Chavkin C, Colago EE, Pickel VM (2001). Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42: 185-192. (Pubitemid 32999625)
53. Svingos AL, Colago EE, Pickel VM (1999). Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. J Neurosci 19: 1804-1813. (Pubitemid 29094196)
54. Tejeda HA, Shippenberg TS, Henriksson R (2012). The dynorphin/ kappa-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 69: 857-896.
55. Thompson AC, Zapata A, Justice JB Jr., Vaughan RA, Sharpe LG, Shippenberg TS (2000). Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20: 9333-9340. (Pubitemid 32042938)
56. Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA Jr. (2008). The kappa-opioid agonist U69, 593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64: 982-988.
57. Valjent E, Bertran-Gonzalez J, Aubier B, Greengard P, Herve D, Girault JA (2010). Mechanisms of locomotor sensitization to drugs of abuse in a two-injection protocol. Neuropsychophar-macology 35: 401-415.
58. Van't Veer A, Yano JM, Carroll FI, Cohen BM, Carlezon WA Jr. (2012). Corticotropin-releasing factor (crf)-induced disruption of attention in rats is blocked by the kappa-opioid receptor antagonist JDTic. Neuropsychopharmacology 37: 2809-2816.
59. Walker BM, Valdez GR, McLaughlin JP, Bakalkin G (2012). Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence. Alcohol 46: 359-370.
60. Wang YJ, Rasakham K, Huang P, Chudnovskaya D, Cowan A, Liu-Chen LY (2011). Sex difference in kappa-opioid receptor (KOPR)-mediated behaviors, brain region KOPR level and KOPR-mediated guanosine 5'-O-(3-[35S]thiotriphosphate) binding in the guinea pig. J Pharmacol Exp Ther 339: 438-450.
61. Wee S, Koob GF (2010). The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychophar-macology 210: 121-135.
62. Wise RA, Bozarth MA (1987). A psychomotor stimulant theory of addiction. Psychol Rev 94: 469-492.